SCHEMBL4488977

SCHEMBL4488977

COc1ccc(-c2sc(CNS(=O)(=O)c3cc(F)cc(F)c3)cc2-c2ccc(Cl)cc2Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TP53 P04637 1/20 0.42
NR3C1 P04150 1/20 0.40
PGR P06401 1/20 0.40
CNR1 P21554 2/20 0.40
ALDH1A1 P00352 3/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
EP300 Q09472 1/20 0.38
CYP3A4 P08684 2/20 0.37
LMNA P02545 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP19A1 P11511 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496378 0.93 MAPT (0.51) MAPTSMN1; SMN2TP53NR3C1PGR
SCHEMBL4490302 0.92 ALDH1A1 (0.41) MAPTSMN1; SMN2TP53NR3C1PGR
SCHEMBL4494987 0.90 ALDH1A1 (0.47) MAPTSMN1; SMN2TP53CNR1ALDH1A1
SCHEMBL4492694 0.90 MAPT (0.41) MAPTSMN1; SMN2TP53CNR1ALDH1A1
SCHEMBL4508001 0.90 CNR1 (0.43) MAPTSMN1; SMN2CNR1ALDH1A1POLB
SCHEMBL4505757 0.88 PGR (0.48) MAPTSMN1; SMN2PGRCNR1ALDH1A1
SCHEMBL4491425 0.87 FLT1 (0.47) MAPTSMN1; SMN2PGRALDH1A1POLB
SCHEMBL4500266 0.86 CNR1 (0.39) MAPTSMN1; SMN2TP53NR3C1PGR
SCHEMBL4493774 0.86 CNR1 (0.41) MAPTSMN1; SMN2TP53CNR1ALDH1A1
SCHEMBL4488378 0.85 MAPT (0.52) MAPTSMN1; SMN2TP53NR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589120-B2 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-15 US claimed
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-12-13 US claimed
US-7589120-B2 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-15 US disclosed
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-12-13 US disclosed
EP-1841754-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-10-10 EP disclosed
WO-2006077320-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION TPMT, TXNRD2, ARG2 MAPT 4238/4885SMN1; SMN2 144/4885TP53 2861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.